CTLA4 and non-small cell lung carcinoma: In metastatic NSCLC, two single-institution prospective trials showed a significantly better PFS with anti-PD-1 combined with SBRT than with anti-CTLA4 (6-month PFS, 87% vs. 52%; 18-month PFS, 63% vs. 23%; P = 0.02) [132].